News

Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets Zydus Lifesciences is currently trading at Rs. 556.30, up by 1.95 points or 0.35% from its previous closing of Rs. 554.35 on the BSE. The scrip opened at Rs. 556.00 and has touched a high and low of Rs. 558.00 and Rs. 553.80 respectively. So far 16064 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 562.15 on 19-Jun-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets
Source: Accord Fintech
20/06/2023 10:46:26 AM
Zydus Lifesciences inches up on getting USFDA’s final nod for Famotidine Tablets Zydus Lifesciences is currently trading at Rs. 364.60, up by 1.65 points or 0.45% from its previous closing of Rs. 362.95 on the BSE. The scrip opened at Rs. 360.00 and has touched a high and low of Rs. 364.60 and Rs. 358.00 respectively. So far 6682 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting USFDA’s final nod for Famotidine Tablets
Zydus Lifesciences inches up on getting USFDA’s final nod for Famotidine Tablets
Source: Accord Fintech
6/06/2022 10:11:34 AM
Zydus Lifesciences jumps on getting USFDA’s approval for Pemetrexed for Injection Zydus Lifesciences is currently trading at Rs. 369.85, up by 3.60 points or 0.98% from its previous closing of Rs. 366.25 on the BSE. The scrip opened at Rs. 368.95 and has touched a high and low of Rs. 372.60 and Rs. 363.80 respectively. So far 47123 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences jumps on getting USFDA’s approval for Pemetrexed for Injection
Zydus Lifesciences jumps on getting USFDA’s approval for Pemetrexed for Injection
Source: Accord Fintech
26/05/2022 3:21:21 PM
Zydus Lifesciences zooms despite reporting 41% fall in Q4 consolidated net profit Zydus Lifesciences is currently trading at Rs. 365.60, up by 8.45 points or 2.37% from its previous closing of Rs. 357.15 on the BSE. The scrip opened at Rs. 372.00 and has touched a high and low of Rs. 372.00 and Rs. 357.65 respectively. So far 149864 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences zooms despite reporting 41% fall in Q4 consolidated net profit
Zydus Lifesciences zooms despite reporting 41% fall in Q4 consolidated net profit
Source: Accord Fintech
23/05/2022 1:42:08 PM
Zydus Lifesciences zooms on launching Bemdac to treat uncontrolled LDL-c Zydus Lifesciences is currently trading at Rs. 343.45, up by 10.00 points or 3.00% from its previous closing of Rs. 333.45 on the BSE. The scrip opened at Rs. 335.00 and has touched a high and low of Rs. 344.45 and Rs. 335.00 respectively. So far 48128 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences zooms on launching Bemdac to treat uncontrolled LDL-c
Zydus Lifesciences zooms on launching Bemdac to treat uncontrolled LDL-c
Source: Accord Fintech
13/05/2022 2:46:36 PM
Zydus Lifesciences trades in green on planning to manufacture, supply Sagent’s Caffeine Citrate Oral Solution Zydus Lifesciences is currently trading at Rs. 365.60, up by 2.50 points or 0.69% from its previous closing of Rs. 363.10 on the BSE. The scrip opened at Rs. 367.00 and has touched a high and low of Rs. 369.00 and Rs. 361.25 respectively. So far 31125 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences trades in green on planning to manufacture, supply Sagent’s Caffeine Citrate Oral Solution
Zydus Lifesciences trades in green on planning to manufacture, supply Sagent’s Caffeine Citrate Oral Solution
Source: Accord Fintech
13/04/2022 3:34:26 PM
Zydus Lifesciences moves up on getting PAS approval from USFDA for Mycophenolate Mofetil for Injection Zydus Lifesciences is currently trading at Rs. 376.20, up by 3.00 points or 0.80% from its previous closing of Rs. 373.20 on the BSE. The scrip opened at Rs. 375.00 and has touched a high and low of Rs. 376.20 and Rs. 373.00 respectively. So far 1701 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences moves up on getting PAS approval from USFDA for Mycophenolate Mofetil for Injection
Zydus Lifesciences moves up on getting PAS approval from USFDA for Mycophenolate Mofetil for Injection
Source: Accord Fintech
21/03/2022 9:58:19 AM
Zydus Lifesciences jumps as its arm executes asset purchase agreement with BridgeBio Zydus Lifesciences is currently trading at Rs. 355.70, up by 11.85 points or 3.45% from its previous closing of Rs. 343.85 on the BSE. The scrip opened at Rs. 350.75 and has touched a high and low of Rs. 360.50 and Rs. 348.00 respectively. So far 40236 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences jumps as its arm executes asset purchase agreement with BridgeBio
Zydus Lifesciences jumps as its arm executes asset purchase agreement with BridgeBio
Source: Accord Fintech
9/03/2022 1:19:36 PM
Key News - Cadila Healthcare, IndiGo , Hindustan, IKEA Navi Mumbai,Indian Oil Corporation,By ARETE Securities Key News Standard Chartered, IATA tie up forh payment platform for airline industry Global banking group Standard Chartered on Thursday said it has partnered with the International Air Transport Association (IATA) to launch a payment platform for airline industry in India. In addition to existing payment options such as credit cards, IATA Pay will be a new payment option that enables participating airlines to offer instant payment options such as UPI Scan and Pay and UPI Collect (Req...
Key News - Cadila Healthcare, IndiGo , Hindustan, IKEA Navi Mumbai,Indian Oil Corporation,By ARETE Securities
Key News - Cadila Healthcare, IndiGo , Hindustan, IKEA Navi Mumbai,Indian Oil Corporation,By ARETE Securities
Source: ARETE Securities Ltd
25/02/2022 9:10:34 AM
Key News - Urban Company, Realme, Lupin Ltd, Volkswagen, Vedanta Ltd, Zydus Cadila Healthcare Ltd By ARETE Securities Key News Urban Company's valuation rises to $2.8 billion in 4th ESOP sale programme Home services marketplace Urban Company’s valuation has jumped 33 per cent in the past six months to $2.8 billion, thanks to its recently concluded fourth and largest employee stock ownership plan (ESOP) sale programme of $7.3 million (Rs 55 crore). The ESOPs sold in this transaction have largely been purchased by existing institutional investors of the company. The company’s valuation wa...
Key News - Urban Company, Realme, Lupin Ltd, Volkswagen, Vedanta Ltd, Zydus Cadila Healthcare Ltd By ARETE Securities
Key News - Urban Company, Realme, Lupin Ltd, Volkswagen, Vedanta Ltd, Zydus Cadila Healthcare Ltd By ARETE Securities
Source: ARETE Securities Ltd
13/12/2021 10:49:35 AM
Key News - Pidilite Industries Ltd, PTC India, Bajaj Electricals Ltd, Bata India Ltd, PNB Housing Finance, Zydus Cadila Healthcare Ltd By ARETE Securities Key News Pidilite PAT jumps 12.7 times in Q1 to Rs 217.6 cr; revenue rises 121% Adhesive major Pidilite Industries reported a 1,277 percent year-on-year (YoY) jump in its profit after tax (PAT) for the April-June quarter. Net profit for the quarter stood at Rs 217.6 crore, up from Rs 15.8 crore in the corresponding quarter last year. Its operating revenue grew 121 percent to Rs 1,936.8 crore from Rs 877.8 crore. In comparison to its pre-COVID performance, Pidilite’s top-line and b...
Key News - Pidilite Industries Ltd, PTC India, Bajaj Electricals Ltd, Bata India Ltd, PNB Housing Finance, Zydus Cadila Healthcare Ltd By ARETE Securities
Key News - Pidilite Industries Ltd, PTC India, Bajaj Electricals Ltd, Bata India Ltd, PNB Housing Finance, Zydus Cadila Healthcare Ltd By ARETE Securities
Source: ARETE Securities Ltd
12/08/2021 9:12:44 AM
Key News - Eicher Motors Ltd, India Grid Trust Ltd, Page Industries Ltd, Zydus Cadila Healthcare Ltd, Goodyear India Ltd, IRB Infrastructure Developers Ltd by ARETE Securities Key News Eicher Motors' profit after tax jumps 73% to Rs 526 cr in March quarter Eicher Motors Ltd on Thursday reported a 73 per cent jump in consolidated profit after tax at Rs 526.14 crore for the fourth quarter ended March 31, 2021, riding on better sales. The company had posted a consolidated profit after tax of Rs 304.28 crore in the fourth quarter of the previous fiscal, Eicher Motors Ltd said in a regulatory filing. Its consolidated total revenue from operations in January-Ma...
Key News - Eicher Motors Ltd, India Grid Trust Ltd, Page Industries Ltd, Zydus Cadila Healthcare Ltd, Goodyear India Ltd, IRB Infrastructure Developers Ltd by ARETE Securities
Key News - Eicher Motors Ltd, India Grid Trust Ltd, Page Industries Ltd, Zydus Cadila Healthcare Ltd, Goodyear India Ltd, IRB Infrastructure Developers Ltd by ARETE Securities
Source: ARETE Securities Ltd
28/05/2021 9:14:49 AM
India`s Zydus Cadila seeks human trial approval for COVID-19 antibody cocktail BENGALURU  - India's Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as the country grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic. The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated. The therapy is a cocktail of two monoclona...
India`s Zydus Cadila seeks human trial approval for COVID-19 antibody cocktail
India`s Zydus Cadila seeks human trial approval for COVID-19 antibody cocktail
Source: Reuters
27/05/2021 11:20:01 AM
Zydus launches Ujvira, breakthrough in breast cancer treatment Zydus Cadila launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name 'Ujvira'. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25 per cent of all Breast Cancers. In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial. The curr...
Zydus launches Ujvira, breakthrough in breast cancer treatment
Zydus launches Ujvira, breakthrough in breast cancer treatment
Source: IANS
24/05/2021 1:56:07 PM
Zydus launches Ujvira , a breakthrough in Breast Cancer treatment launched in India By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Zydus launches Ujvira , a breakthrough in Breast Cancer treatment launched in India by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd      Zydus launches Ujvira (Trastuzumab Emtansine), a breakthrough in Breast Cancer treatment launched in India Launch marks the World’s first biosimilar Antibody Drug Conjugate of Trastuzumab Emtansine. The therapy will be priced at nearly 80% less than the currently ...
Zydus launches Ujvira , a breakthrough in Breast Cancer treatment launched in India By Mr. Yash Gupta, Angel Broking Ltd
Zydus launches Ujvira , a breakthrough in Breast Cancer treatment launched in India By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
24/05/2021 12:25:48 PM
Zydus Cadila to sell its India focused animal health biz for Rs 2,921 cr to Multiples, RARE Zydus Animal Health and Investments Limited (ZAHL) a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium. Zydus AH is the animal health business of ZAHL focused on India and certain other countries. The consortium, including Canada Pension Plan Investment Board and RAR...
Zydus Cadila to sell its India focused animal health biz for Rs 2,921 cr to Multiples, RARE
Zydus Cadila to sell its India focused animal health biz for Rs 2,921 cr to Multiples, RARE
Source: IANS
12/05/2021 1:32:56 PM
Buy Cadila Healthcare Ltd Target Rs. 480 - Religare Broking Religare Super Idea**   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Above views are of the author and not of the website kindly read disclaimer
Buy Cadila Healthcare Ltd Target Rs. 480 - Religare Broking
Buy Cadila Healthcare Ltd Target Rs. 480 - Religare Broking
Source: Religare Broking Ltd
7/04/2021 9:51:36 AM